Use of biomarkers to diagnose and manage cardiac amyloidosis. (21st February 2021)

• Record Type: Journal Article
• Authors: Castiglione, Vincenzo; Franzini, Maria; Aimo, Alberto; Carecci, Alessandro; Lombardi, Carlo Mario; Passino, Claudio; Rapezzi, Claudio; Emdin, Michele; Vergaro, Giuseppe
• Is Part Of: European journal of heart failure. Volume 23:Number 2(2021)
• Page Start: 217
• Page End: 230
• Publication Date: 2021-02-21
• Subjects: Biomarkers -- Amyloidosis -- NT‐proBNP -- Troponin -- Free light chains; Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.2113
• Languages: English
• ISSNs: 1388-9842

Abstract

Abstract : Amyloidoses are characterized by the tissue accumulation of misfolded proteins into insoluble fibrils. The two most common types of systemic amyloidosis result from the deposition of immunoglobulin light chains (AL) and wild‐type or variant transthyretin (ATTRwt/ATTRv). Cardiac involvement is the main determinant of outcome in both AL and ATTR, and cardiac amyloidosis (CA) is increasingly recognized as a cause of heart failure. In CA, circulating biomarkers are important diagnostic tools, allow to refine risk stratification at baseline and during follow‐up, help to tailor the therapeutic strategy and monitor the response to treatment. Among amyloid precursors, free light chains are established biomarkers in AL amyloidosis, while the plasma transthyretin assay is currently being investigated as a tool for supporting the diagnosis of ATTRv amyloidosis, predicting outcome and monitor response to novel tetramer stabilizers or small interfering RNA drugs in ATTR CA. Natriuretic peptides (NPs) and troponins are consistently elevated in patients with AL and ATTR CA. Plasma NPs, troponins and free light chains hold prognostic significance in AL amyloidosis, and are evaluated for therapy decision‐making and follow‐up, while the value of NPs and troponins in ATTR is less well established. Biomarkers can be usefully integrated with clinical and imaging variables at all levels of the clinical algorithm of systemic amyloidosis, from screening to diagnosis and prognosis, and treatment tailoring. Abstract :